Clinical trial

A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)

NCT07361497

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2026-03-16

PhasePHASE3

Study timeline

Study start (actual)2026-03-16Date precision: day

Registry last updated2026-09-30

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Non-small Cell Lung Cancer (NSCLC)unresolved

Interventions

PumitamigDRUG

DurvalumabDRUG · verified · RxNorm: durvalumab

Sponsors & collaborators

Bristol-Myers Squibblead sponsor

BioNTech SEcollaborator

Mapped research locations

BerlinGermany3 Buenos AiresArgentina3 SofiaBulgaria3 NashvilleTennessee, United States2 LondonUnited Kingdom2 ClevelandOhio, United States2 MilanItaly2 IstanbulTurkey (Türkiye)2 HangzhouZhejiang, China2 SingaporeSingapore2 WuhanHubei, China2 ChengduSichuan, China2

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT07361497 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.